OncoMed says CMO Dupont has resigned and expects return to Genentech/Roche
Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan
This iShares’ ETF has appeal, but investors don't have to go much further afield to find more-compelling options.
First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.
These quality funds with smaller asset bases have portfolios built around solid companies.
Large drugmakers are out of favor, but some good funds are banking on a rebound.
As incomes rise, emerging-markets consumers can afford more and better medications driving attractive growth in the pharmaceuticals sector, say the managers of Dodge & Cox International Stock.